Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

September 8th 2023

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr Deol on Sequencing Treatment Options With CAR T-Cell Therapy in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

September 7th 2023

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1

September 7th 2023

Yi Lin, MD, PhD, the predictive value of baseline characteristics in relation to sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma

September 4th 2023

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

Role of Diagnostic Testing in Patients with Multiple Myeloma

September 4th 2023

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

Dr Tauro on the Rationale for Investigating ULK3 in Multiple Myeloma

September 1st 2023

Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.

Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma

August 30th 2023

Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dara-KRd Quadruplet Makes Waves in Newly Diagnosed Multiple Myeloma

August 25th 2023

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

Talquetamab Wins Approval in Europe for Relapsed/Refractory Myeloma

August 22nd 2023

The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy.

Dr Schinke on the Safety Profile of Talquetamab in Relapsed/Refractory Myeloma

August 21st 2023

Carolina D. Schinke, MD, discusses the safety profile of talquetamab-tgvs in the phase 1/2 MonumenTAL-1 trial of patients with relapsed/refractory multiple myeloma.

Educating on Multiple Myeloma: Patient and Physician Resources

August 21st 2023

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care

August 21st 2023

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma

August 18th 2023

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.

European Commission Approves Reduced Dosing of Teclistamab in Relapsed/Refractory Myeloma

August 18th 2023

The European Commission has approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved a complete response or better for a minimum of 6 months.

Dr Schinke on the Rationale for the MonumenTAL-1 Trial in Multiple Myeloma

August 16th 2023

Carolina D. Schinke, MD, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma

August 16th 2023

Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.

Dr Patel on Maintaining Quality of Life While Treating Patients With Multiple Myeloma

August 15th 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

FDA Lifts Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma

August 15th 2023

The FDA has lifted the partial clinical hold placed on the clinical program evaluating the investigational new drug, CART-ddBCMA, in the treatment of patients with relapsed/refractory multiple myeloma.